ICICI Prudential Asset Management Co Ltd cut its stake in shares of Kenvue Inc. (NYSE:KVUE – Free Report) by 9.5% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 514,460 shares of the company’s stock after selling 54,100 shares during the quarter. ICICI Prudential Asset Management Co Ltd’s holdings in Kenvue were worth $9,085,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors also recently made changes to their positions in KVUE. Johnson Financial Group Inc. bought a new position in Kenvue during the 2nd quarter valued at about $26,000. GK Wealth Management LLC bought a new stake in Kenvue during the third quarter worth about $27,000. CoreCap Advisors LLC grew its stake in Kenvue by 64.9% during the second quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock worth $29,000 after buying an additional 591 shares during the last quarter. Bell Investment Advisors Inc acquired a new stake in shares of Kenvue during the second quarter worth approximately $35,000. Finally, Bank Julius Baer & Co. Ltd Zurich acquired a new stake in shares of Kenvue during the third quarter worth approximately $36,000. 97.64% of the stock is owned by institutional investors.
Analysts Set New Price Targets
KVUE has been the subject of a number of research analyst reports. HSBC cut their target price on shares of Kenvue from $20.00 to $19.00 and set a “hold” rating for the company in a research note on Monday, August 10th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kenvue in a report on Friday, September 11th. Wall Street Zen cut Kenvue from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Barclays lifted their price objective on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 21st. Finally, UBS Group boosted their price objective on Kenvue from $19.00 to $20.00 and gave the stock a “neutral” rating in a research note on Monday, November 2nd. Ten equities research analysts have rated the stock with a Hold rating. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $19.29.
Check Out Our Latest Stock Report on KVUE
Kenvue Stock Performance
Shares of NYSE KVUE opened at $19.31 on Monday. Kenvue Inc. has a 1-year low of $14.06 and a 1-year high of $20.13. The company has a market cap of $37.09 billion, a PE ratio of 21.94, a P/E/G ratio of 1.77 and a beta of 0.48. The company has a current ratio of 1.01, a quick ratio of 0.71 and a debt-to-equity ratio of 0.67. The company has a 50-day moving average of $18.45 and a two-hundred day moving average of $18.28.
Kenvue (NYSE:KVUE – Get Free Report) last announced its earnings results on Friday, October 30th. The company reported $0.29 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.29. Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The company had revenue of $3.89 billion for the quarter, compared to analyst estimates of $3.86 billion. During the same period in the prior year, the business earned $0.28 earnings per share. Kenvue’s quarterly revenue was up 3.2% on a year-over-year basis. As a group, equities analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.
Kenvue Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Friday, October 2nd. Stockholders of record on Monday, September 21st were given a dividend of $0.21 per share. The ex-dividend date was Monday, September 21st. This represents a $0.84 dividend on an annualized basis and a dividend yield of 4.4%. Kenvue’s payout ratio is presently 95.45%.
Kenvue Company Profile
Kenvue Inc. is a consumer health company that develops and sells products for everyday health and personal care. Its portfolio includes over-the-counter medicines, skin and hair care, oral care, wound care, and baby care products. Its well-known brands include Tylenol, Neutrogena, Aveeno, Listerine, Band-Aid, Johnson’s, and Zyrtec. Kenvue organizes its business around Self Care, Skin Health and Beauty, and Essential Health. The company became an independent business in 2023 after Johnson & Johnson completed the separation of its consumer health business.
Further Reading
- Five stocks we like better than Kenvue
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE – Free Report).
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.
